Spain’s credit rating upgraded to ’A+’ by S&P on strong growth
Investing.com - JMP Securities has reiterated its Market Outperform rating and $6.00 price target on Taysha Gene Therapies (NASDAQ:TSHA), which is developing TSHA-102 for Rett Syndrome. The company, currently valued at $884 million, has seen its stock surge 86% over the past six months and trades near its 52-week high of $3.40. According to InvestingPro data, analyst price targets range from $5 to $14.
The gene therapy treatment employs an unmodified AAV9 vector delivered intrathecally, providing consistent distribution across the brain and spinal cord with minimal invasiveness and without systemic exposure of the AAV.
TSHA-102 has been administered to 12 patients at doses of 5.7E14 or 1E15 vg with zero serious treatment-emergent adverse events related to the therapy, according to JMP.
Following written alignment from the FDA on key elements of the pivotal trial design, Taysha plans to begin patient enrollment in the fourth quarter of 2025.
JMP notes that Astellas has an option to negotiate for rights to TSHA-102, and a potential offer from Astellas could emerge in the coming months.
In other recent news, Taysha Gene Therapies reported its financial results for the second quarter of 2025, with revenue surpassing expectations. The company posted $1.98 million in revenue, exceeding the forecasted $1.82 million, resulting in an 8.79% surprise. However, the earnings per share showed a loss of $0.09, slightly missing the anticipated loss of $0.08. Additionally, Canaccord Genuity raised its price target for Taysha Gene Therapies from $11.00 to $14.00, maintaining a Buy rating. This decision followed the company’s second-quarter earnings report and the progress in its TSHA-102 pivotal REVEAL Part B study. The study remains on track, with site activations ongoing and patient enrollment expected to begin in the fourth quarter of 2025. These developments reflect the company’s continued efforts in advancing its research and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.